Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 9Neoplasms 5Breast Neoplasms 5Neoplasm Metastasis 4Kidney Neoplasms 3Carcinoma, Renal Cell 3Multiple Myeloma 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Parathyroid Neoplasms 1Osteoporosis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Hypercalcemia 1Humoral Hypercalcemia Of Malignancy 1Hormone Refractory Prostate Cancer 1Hodgkin Disease 1Head and Neck Neoplasms 1Endocrine Gland Neoplasms 1Colonic Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Cataract 1Castrate-resistant Prostate Cancer 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Bone Diseases, Metabolic 1

Interventions

Docetaxel 4radium Ra 223 dichloride 2Prednisone 2sargramostim 1gossypol acetic acid 1epothilone B 1cabazitaxel 1bafetinib 1Sunitinib 1PE regimen 1Mycobacterium w vaccine 1Interleukin-2 1Injections 1Everolimus 1Etoposide 1Denosumab 1Cyclophosphamide 1Cisplatin 1Carboplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone Refractory Prostate Cancer × Denosumab × Genitourinary × Clear all
NCT00286091 2018-10-17

Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Amgen

Phase 3 Completed
1,435 enrolled 15 charts
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡